Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

Abstract

BACKGROUND:

Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalographic discharges, developmental deterioration, and early mortality. Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical marijuana with anecdotal success.

PATIENT DESCRIPTION:

We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen.

CONCLUSION:

This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy.

• Authors: Dimah Saade, Charuta Joshi
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 52 Issue 5 Pg. 544-7 (May 2015) ISSN: 1873-5150 [Electronic] United States
• PMID: 25882081 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Anticonvulsants
• Cannabidiol

Topics

• Anticonvulsants (therapeutic use)
• Cannabidiol (therapeutic use)
• Electroencephalography
• Epilepsies, Partial (drug therapy)
• Humans
• Infant
• Male